The Goldman Sachs S&P 500 Premium Income ETF (GPIX) uses a conservative covered-call strategy on S&P 500 stocks, aiming to balance monthly income with potential equity gains. It maintains a lower call overwrite rate of about 30%, focusing on total returns rather than maximizing yield, and has delivered approximately 21% annualized returns since inception. This ETF suits investors seeking steady income with exposure to the S&P 500, especially in flat or moderately rising markets. However, risks include limited downside protection, potential missed gains in strong bull markets, and higher fees compared to passive index funds.
The Goldman Sachs S&P 500 Premium Income ETF (GPIX) is the subject, with Pluang market data as context. As of Oct 26, 2026 16:41 WIB, out of 150 priced US stocks tradable on Pluang, 96 rose and 47 fell today. Notable movers include MRNA at USD 187.00 with a -6.55% change, VALE at USD 11.90 with a -4.03% change, and GFI at USD 35.70 with a +3.21% change. The most notable figure is MRNA's -6.55% 1-day change.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
